Cargando…

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

BACKGROUND: Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheffler, Armin, Messel, Olga, Wurthmann, Sebastian, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Naegel, Steffen, Holle, Dagny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333436/ https://www.ncbi.nlm.nih.gov/pubmed/32620151 http://dx.doi.org/10.1186/s10194-020-01151-0

Ejemplares similares

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
por: Schenk, Hannah, et al.
Publicado: (2022)

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
por: Scheffler, Armin, et al.
Publicado: (2021)

Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
por: Nsaka, Michael, et al.
Publicado: (2022)

Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study
por: Wurthmann, Sebastian, et al.
Publicado: (2021)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Persistent Postural-Perceptual Dizziness: A Matter of Higher, Central Dysfunction?
por: Holle, Dagny, et al.
Publicado: (2015)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

Polarity-specific modulation of pain processing by transcranial direct current stimulation – a blinded longitudinal fMRI study
por: Naegel, Steffen, et al.
Publicado: (2018)

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
por: Silvestro, Marcello, et al.
Publicado: (2021)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
por: Andreou, Anna P., et al.
Publicado: (2022)

Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
por: Straube, Andreas, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

EHMTI-0124. Central vestibular system modulation in vestibular migraine - a VBM study
por: Wurthmann, S, et al.
Publicado: (2014)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
por: Hong, Ja Bin, et al.
Publicado: (2023)

Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice
por: Storch, P., et al.
Publicado: (2021)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Influences of smoking and caffeine consumption on trigeminal pain processing
por: Holle, Dagny, et al.
Publicado: (2014)

Recent advances in the management of migraine
por: Obermann, Mark, et al.
Publicado: (2016)

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
por: Gantenbein, Andreas R., et al.
Publicado: (2022)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
por: Maraia, Zaira, et al.
Publicado: (2021)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
por: Russo, Antonio, et al.
Publicado: (2020)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
por: Gantenbein, Andreas R., et al.
Publicado: (2022)

Cortical plasticity in episodic and chronic cluster headache
por: Naegel, Steffen, et al.
Publicado: (2014)

Patient-conducted anodal transcranial direct current stimulation of the motor cortex alleviates pain in trigeminal neuralgia
por: Hagenacker, Tim, et al.
Publicado: (2014)

Short Latency Gray Matter Changes in Voxel-Based Morphometry following High Frequent Visual Stimulation
por: Naegel, Steffen, et al.
Publicado: (2017)

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
por: Lanteri-Minet, M., et al.
Publicado: (2023)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h8fbh17n96gljrvgoquflbbg10